ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Glucagon-like Peptide-2 (GLP-2) Agonist - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: October 2024
|
Report Code: QYRE-Auto-32F944
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Glucagon like Peptide 2 GLP 2 Agonist Market Research Report 2020
BUY CHAPTERS

Glucagon-like Peptide-2 (GLP-2) Agonist - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-32F944
Report
October 2024
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Takeda Pharmaceuticals

Glucagon-like Peptide-2 (GLP-2) Agonist - Market Size

The global market for Glucagon-like Peptide-2 (GLP-2) Agonist was estimated to be worth US$ 751 million in 2023 and is forecast to a readjusted size of US$ 2122.1 million by 2030 with a CAGR of 16.0% during the forecast period 2024-2030

Glucagon-like Peptide-2 (GLP-2) Agonist - Market

Glucagon-like Peptide-2 (GLP-2) Agonist - Market

Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome.
The Teduglutide market is primarily driven by the demand for innovative therapies to address short bowel syndrome (SBS) and improve the quality of life for affected patients. Teduglutide is a medication used to treat SBS, a condition characterized by impaired intestinal function due to surgical resection or congenital anomalies. The limited treatment options for SBS, coupled with advancements in gastrointestinal medicine and patient-centric care, contribute to market growth. Moreover, the demonstrated efficacy of Teduglutide in reducing dependence on parenteral nutrition and enhancing nutrient absorption further propels adoption. However, challenges include managing potential side effects and addressing patient access issues. Navigating regulatory approvals, optimizing treatment regimens, and ensuring long-term safety and efficacy are ongoing concerns. The market's success relies on continuous research in gastrointestinal disorders, collaborations between pharmaceutical manufacturers and gastroenterologists, and comprehensive patient education on the benefits and potential risks of Teduglutide treatment while addressing the evolving challenges associated with SBS management and treatment accessibility.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Glucagon-like Peptide-2 (GLP-2) Agonist, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Glucagon-like Peptide-2 (GLP-2) Agonist by region & country, by Type, and by Application.
The Glucagon-like Peptide-2 (GLP-2) Agonist market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucagon-like Peptide-2 (GLP-2) Agonist.
Market Segmentation

Scope of Glucagon-like Peptide-2 (GLP-2) Agonist - Market Report

Report Metric Details
Report Name Glucagon-like Peptide-2 (GLP-2) Agonist - Market
Forecasted market size in 2030 US$ 2122.1 million
CAGR 16.0%
Forecasted years 2024 - 2030
Segment by Type:
  • Gattex
  • Revestive
Segment by Application
  • Hospital
  • Pharmacy
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Takeda Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Glucagon-like Peptide-2 (GLP-2) Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Glucagon-like Peptide-2 (GLP-2) Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Glucagon-like Peptide-2 (GLP-2) Agonist in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Glucagon-like Peptide-2 (GLP-2) Agonist - Market size in 2030?

Ans: The Glucagon-like Peptide-2 (GLP-2) Agonist - Market size in 2030 will be US$ 2122.1 million.

Who are the main players in the Glucagon-like Peptide-2 (GLP-2) Agonist - Market report?

Ans: The main players in the Glucagon-like Peptide-2 (GLP-2) Agonist - Market are Takeda Pharmaceuticals

What are the Application segmentation covered in the Glucagon-like Peptide-2 (GLP-2) Agonist - Market report?

Ans: The Applications covered in the Glucagon-like Peptide-2 (GLP-2) Agonist - Market report are Hospital, Pharmacy, Other

What are the Type segmentation covered in the Glucagon-like Peptide-2 (GLP-2) Agonist - Market report?

Ans: The Types covered in the Glucagon-like Peptide-2 (GLP-2) Agonist - Market report are Gattex, Revestive

1 Market Overview
1.1 Glucagon-like Peptide-2 (GLP-2) Agonist Product Introduction
1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast
1.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2019-2030)
1.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume (2019-2030)
1.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price (2019-2030)
1.3 Glucagon-like Peptide-2 (GLP-2) Agonist Market Trends & Drivers
1.3.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends
1.3.2 Glucagon-like Peptide-2 (GLP-2) Agonist Market Drivers & Opportunity
1.3.3 Glucagon-like Peptide-2 (GLP-2) Agonist Market Challenges
1.3.4 Glucagon-like Peptide-2 (GLP-2) Agonist Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Players Revenue Ranking (2023)
2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Company (2019-2024)
2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Players Sales Volume Ranking (2023)
2.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Company Players (2019-2024)
2.5 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Company (2019-2024)
2.6 Key Manufacturers Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Glucagon-like Peptide-2 (GLP-2) Agonist Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Glucagon-like Peptide-2 (GLP-2) Agonist
2.9 Glucagon-like Peptide-2 (GLP-2) Agonist Market Competitive Analysis
2.9.1 Glucagon-like Peptide-2 (GLP-2) Agonist Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Glucagon-like Peptide-2 (GLP-2) Agonist Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like Peptide-2 (GLP-2) Agonist as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Gattex
3.1.2 Revestive
3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type
3.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, by Type (2019-2030)
3.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, by Type (%) (2019-2030)
3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type
3.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume, by Type (2019-2030)
3.3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume, by Type (%) (2019-2030)
3.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.1.3 Other
4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application
4.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, by Application (2019-2030)
4.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, by Application (%) (2019-2030)
4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application
4.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume, by Application (2019-2030)
4.3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume, by Application (%) (2019-2030)
4.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region
5.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region (2019-2024)
5.1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region (2025-2030)
5.1.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region (%), (2019-2030)
5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Region
5.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Region (2019-2024)
5.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Region (2025-2030)
5.2.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Region (%), (2019-2030)
5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
5.4.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
5.5.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
5.6.2 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
5.7.2 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
5.8.2 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value
6.2.1 Key Countries/Regions Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
6.2.2 Key Countries/Regions Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
6.3.2 United States Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
6.4.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
6.5.2 China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
6.5.3 China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
6.6.2 Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
6.7.2 South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
6.8.2 Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019-2030
6.9.2 India Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
6.9.3 India Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Takeda Pharmaceuticals
7.1.1 Takeda Pharmaceuticals Company Information
7.1.2 Takeda Pharmaceuticals Introduction and Business Overview
7.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Offerings
7.1.5 Takeda Pharmaceuticals Recent Development
8 Industry Chain Analysis
8.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industrial Chain
8.2 Glucagon-like Peptide-2 (GLP-2) Agonist Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Glucagon-like Peptide-2 (GLP-2) Agonist Sales Model
8.5.2 Sales Channel
8.5.3 Glucagon-like Peptide-2 (GLP-2) Agonist Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Takeda Pharmaceuticals
List of Tables
    Table 1. Glucagon-like Peptide-2 (GLP-2) Agonist Market Trends
    Table 2. Glucagon-like Peptide-2 (GLP-2) Agonist Market Drivers & Opportunity
    Table 3. Glucagon-like Peptide-2 (GLP-2) Agonist Market Challenges
    Table 4. Glucagon-like Peptide-2 (GLP-2) Agonist Market Restraints
    Table 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Company (2019-2024)
    Table 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Glucagon-like Peptide-2 (GLP-2) Agonist Price by Company (2019-2024) & (USD/Unit)
    Table 10. Key Manufacturers Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Glucagon-like Peptide-2 (GLP-2) Agonist Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Glucagon-like Peptide-2 (GLP-2) Agonist
    Table 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like Peptide-2 (GLP-2) Agonist as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2019-2024) & (USD/Unit)
    Table 27. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2025-2030) & (USD/Unit)
    Table 28. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2019-2024) & (USD/Unit)
    Table 39. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2025-2030) & (USD/Unit)
    Table 40. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region (2019-2024) & (%)
    Table 44. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region (2025-2030) & (%)
    Table 45. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Region (2019-2024) & (USD/Unit)
    Table 51. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Region (2025-2030) & (USD/Unit)
    Table 52. Key Countries/Regions Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume, (2025-2030) & (K Units)
    Table 57. Takeda Pharmaceuticals Company Information
    Table 58. Takeda Pharmaceuticals Introduction and Business Overview
    Table 59. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 60. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Offerings
    Table 61. Takeda Pharmaceuticals Recent Development
    Table 62. Key Raw Materials Lists
    Table 63. Raw Materials Key Suppliers Lists
    Table 64. Glucagon-like Peptide-2 (GLP-2) Agonist Downstream Customers
    Table 65. Glucagon-like Peptide-2 (GLP-2) Agonist Distributors List
    Table 66. Research Programs/Design for This Report
    Table 67. Key Data Information from Secondary Sources
    Table 68. Key Data Information from Primary Sources
List of Figures
    Figure 1. Glucagon-like Peptide-2 (GLP-2) Agonist Product Picture
    Figure 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price (2019-2030) & (USD/Unit)
    Figure 6. Glucagon-like Peptide-2 (GLP-2) Agonist Report Years Considered
    Figure 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Glucagon-like Peptide-2 (GLP-2) Agonist Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Glucagon-like Peptide-2 (GLP-2) Agonist Revenue in 2023
    Figure 10. Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Gattex Picture
    Figure 12. Revestive Picture
    Figure 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Market Share by Type, 2023 & 2030
    Figure 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2019-2030) & (USD/Unit)
    Figure 18. Product Picture of Hospital
    Figure 19. Product Picture of Pharmacy
    Figure 20. Product Picture of Other
    Figure 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Market Share by Application, 2023 & 2030
    Figure 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Market Share by Application, 2023 & 2030
    Figure 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2019-2030) & (USD/Unit)
    Figure 26. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2019-2030) & (US$ Million)
    Figure 27. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (%), 2023 VS 2030
    Figure 28. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2019-2030) & (US$ Million)
    Figure 29. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (%), 2023 VS 2030
    Figure 30. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2019-2030) & (US$ Million)
    Figure 31. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (%), 2023 VS 2030
    Figure 32. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2019-2030) & (US$ Million)
    Figure 33. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (%), 2023 VS 2030
    Figure 34. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2019-2030) & (US$ Million)
    Figure 35. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (%), 2023 VS 2030
    Figure 36. Key Countries/Regions Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (%), (2019-2030)
    Figure 37. Key Countries/Regions Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume (%), (2019-2030)
    Figure 38. United States Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, (2019-2030) & (US$ Million)
    Figure 39. United States Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
    Figure 40. United States Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (%), 2023 VS 2030
    Figure 41. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, (2019-2030) & (US$ Million)
    Figure 42. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
    Figure 43. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (%), 2023 VS 2030
    Figure 44. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, (2019-2030) & (US$ Million)
    Figure 45. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
    Figure 46. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (%), 2023 VS 2030
    Figure 47. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, (2019-2030) & (US$ Million)
    Figure 48. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
    Figure 49. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (%), 2023 VS 2030
    Figure 50. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, (2019-2030) & (US$ Million)
    Figure 51. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
    Figure 52. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (%), 2023 VS 2030
    Figure 53. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, (2019-2030) & (US$ Million)
    Figure 54. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
    Figure 55. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (%), 2023 VS 2030
    Figure 56. India Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value, (2019-2030) & (US$ Million)
    Figure 57. India Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (%), 2023 VS 2030
    Figure 58. India Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (%), 2023 VS 2030
    Figure 59. Glucagon-like Peptide-2 (GLP-2) Agonist Industrial Chain
    Figure 60. Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturing Cost Structure
    Figure 61. Channels of Distribution (Direct Sales, and Distribution)
    Figure 62. Bottom-up and Top-down Approaches for This Report
    Figure 63. Data Triangulation
    Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions